Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Arbeitsgemeinschaft medikamentoese Tumortherapie
Gene Solutions
Xencor, Inc.
Exelixis
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Ohio State University Comprehensive Cancer Center
Xencor, Inc.
Incyte Corporation
Roswell Park Cancer Institute
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Vanderbilt-Ingram Cancer Center
Gilead Sciences
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Pfizer
Swiss Cancer Institute
Inovio Pharmaceuticals
Montefiore Medical Center
AbbVie
Hospital Sirio-Libanes
City of Hope Medical Center
Duke University
Angiochem Inc
INSYS Therapeutics Inc
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
NYU Langone Health
NYU Langone Health
Case Comprehensive Cancer Center